Phase II study of combination chemotherapy using paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer.
Phase 2
Recruiting
- Conditions
- cervical cancer
- Registration Number
- JPRN-UMIN000024137
- Lead Sponsor
- Hyogo Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Previous paclitaxel or carboplatin administration within 6 months of registration. 2. Any active concomitant malignancy. 3. Severe comorbidity.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate
- Secondary Outcome Measures
Name Time Method Overall survival, Progression free survival, Toxicity